Medicenna Therapeutics Corp

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

--  Amongst an all-comer population, a single treatment with MDNA55 resulted in at least 100% increase in both 12 month progression free survival (PFS-12 of 27% versus 2 to 10% ) and 2-year survival (OS-24 of 20% vs 5 to10% ) when compared to what is achieved with approved therapies

Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting

TORONTO and HOUSTON, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two abstracts at the EORTC-NCI-AACR ("ENA") Virtual Scientific Program on Molecular Targets and Cancer Therapeutics to be held from October 24 - 25, 2020.

Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting

- After consultation with the FDA, the company can conduct a hybrid registration trial that allows for the use of matched external controls for two-thirds of control arm -

Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)

Medicenna Announces Results of Annual and Special Meeting of Shareholders Medicenna Announces Results of Annual and Special Meeting of Shareholders

Dr. Jack Geltosky Elected to Medicenna Board of Directors

Trading expected to begin August 24, 2020 Trading expected to begin August 24, 2020

Medicenna to Commence Trading on Nasdaq

 - Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55

Medicenna Reports First Quarter Fiscal 2021 Financial Results and Operational Highlights

Medicenna Company Update And Upcoming Catalysts

Medicenna recently demonstrated impressive Phase 2b results with MDNA55, an IL4R targeted therapy, in recurrent glioblastoma in 44 pts. compared to 81 pts. in synthetic control group.

Medicenna's IL4 And IL2 Candidates Both Potentially Best In Class

News for Medicenna Therapeutics Corp Stock (MDNAF)